Business Context and Reporting Period
This Form 8-K Current Report is filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) for the reporting period ending March 2, 2026. The filing discloses significant changes to the company's executive leadership and board composition.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation and severance:
- Severance Cash Payment: $325,000 to be paid over a 12-month period to the departing CEO.
- Equity Grant: $50,000 in restricted common stock to the departing CEO, subject to shareholder approval.
- Benefits: Continued COBRA coverage and equity vesting for the departing CEO during the severance period.
Material Changes
The filing reports the following material changes effective March 2026:
- Appointment of CEO: Michael K. Handley was appointed Chief Executive Officer and a member of the Board of Directors, effective March 3, 2026. He previously served as the Company's Chief Operating Officer and President of Tivic Biopharma since February 2025.
- Resignation of CEO: Jennifer Ernst resigned as Chief Executive Officer effective March 2, 2026, and as a Board member effective March 5, 2026.
- Reason for Departure: Ms. Ernst's resignation was not the result of any dispute or disagreement with the Company regarding operations, policies, or practices.
Outlook, Risks, and Contingencies
Management Commentary: The Company issued a press release on March 4, 2026, announcing the leadership transition. Mr. Handley brings over two decades of experience in drug/device commercialization and regulatory affairs.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to known and unknown risks. No specific new operational risks or contingencies were detailed beyond the standard disclosures.
Investor Verification Checklist
- Verify the exact terms of the Separation Agreement filed as Exhibit 10.1.
- Confirm shareholder approval status for the $50,000 restricted stock grant to the departing CEO.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Note that the registrant is an emerging growth company.